RA Capital Management’s Janux Therapeutics JANX Stock Holding History

RA Capital Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$172M	Hold	11,189,693	–	–	1.49%	17
2026 Q1	$156M	Hold	11,189,693	–	–	1.65%	15
2025 Q4	$154M	Hold	11,189,693	–	–	1.58%	15
2025 Q3	$273M	Hold	11,189,693	–	–	3.37%	10
2025 Q2	$258M	Hold	11,189,693	–	–	4.35%	4
2025 Q1	$302M	Buy	11,189,693 +824,041	+8%	+$31.1M	5.05%	4
2024 Q4	$555M	Buy	10,365,652 +1,200,000	+13%	+$63.5M	7.39%	3
2024 Q3	$416M	Hold	9,165,652	–	–	4.8%	3
2024 Q2	$384M	Hold	9,165,652	–	–	5.08%	3
2024 Q1	$345M	Hold	9,165,652	–	–	4.39%	4
2023 Q4	$98.3M	Hold	9,165,652	–	–	1.54%	16
2023 Q3	$92.4M	Buy	9,165,652 +495,008	+6%	+$5.71M	1.82%	15
2023 Q2	$103M	Hold	8,670,644	–	–	1.94%	13
2023 Q1	$105M	Hold	8,670,644	–	–	2.38%	12
2022 Q4	$114M	Hold	8,670,644	–	–	2.32%	14
2022 Q3	$117M	Hold	8,670,644	–	–	2.5%	10
2022 Q2	$106M	Hold	8,670,644	–	–	2.82%	7
2022 Q1	$124M	Hold	8,670,644	–	–	2.71%	7
2021 Q4	$171M	Hold	8,670,644	–	–	3.02%	5
2021 Q3	$188M	Hold	8,670,644	–	–	2.6%	8
2021 Q2	$216M	Buy	+8,670,644	New	+$193M	3.47%	4

Other funds holding JANX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RA Capital Management's JANX Position: Q2 2026 in Review

RA Capital Management held its Janux Therapeutics (JANX) position steady in Q2 2026 at 11,189,693 shares worth $172M. The position accounts for 1.49% of the portfolio, ranked #17.

RA Capital Management first reported a position in JANX in Q2 2021 and has held it in 21 quarters since. The position peaked at $555M in Q4 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

RA Capital Management held 11,189,693 shares of Janux Therapeutics worth $172M as of Q2 2026.
RA Capital Management left its Janux Therapeutics share count unchanged in Q2 2026.
Janux Therapeutics made up 1.49% of RA Capital Management's portfolio in Q2 2026, its #17 holding.
RA Capital Management first reported a position in Janux Therapeutics in Q2 2021 and has held it in 21 quarters since.
RA Capital Management's Janux Therapeutics position peaked at $555M in Q4 2024.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.